4553-27-9

Usage

Uses

Used in Pharmaceutical Development:
3-(4-Benzyl-piperazinyl)propanamine is used as a precursor in the synthesis of various pharmaceutical compounds for its potential neurological or psychopharmacological properties. It serves as a building block in the creation of drugs that may address specific medical conditions.
Used in Research and Testing:
In the scientific community, 3-(4-Benzyl-piperazinyl)propanamine is utilized as a subject for research and testing to explore its chemical properties, potential interactions with biological systems, and its efficacy and safety in a medical context. This helps in understanding its full potential and limitations in pharmaceutical applications.
Used in Drug Design and Medicinal Chemistry:
3-(4-Benzyl-piperazinyl)propanamine is employed as a key component in drug design and medicinal chemistry, where its structure can be modified or combined with other molecules to create new drugs with desired therapeutic effects. Its unique structure allows for the development of compounds that may have specific binding affinities or activities against certain biological targets.

InChI:InChI=1/C14H23N3/c15-7-4-8-16-9-11-17(12-10-16)13-14-5-2-1-3-6-14/h1-3,5-6H,4,7-13,15H2

Upstream product

• 198478-03-4 3-(4-benzylpiperazin-1-yl) propanenitrile 
• 2759-28-6 1-phenylmethylpiperazine 

Downstream Products

• 1259172-46-7 N-(3-(4-benzylpiperazin-1-yl)propyl)cyclohexanecarboxamide 
• 1082288-31-0 N-(3-(piperazin-1-yl)propyl)cyclohexanecarboxamide 
• 1351411-90-9 N-(3-(4-(6-nitropyridin-2-yl)piperazin-1-yl)propyl)cyclohexanecarboxamide 
• 1351410-70-2 ⁽¹⁸⁾F-N-(3-(4-(6-fluoropyridin-2-yl)piperazin-1-yl)propyl)cyclohexanecarboxamide 

Relevant academic research and scientific papers

Synthesis of 2-(2-oxo-2H-chromen-4-yl)acetamides as potent acetylcholinesterase inhibitors and molecular insights into binding interactions

Sixteen novel coumarin-based compounds are reported as potent acetylcholinesterase (AChE) inhibitors. The most active compound in this series, 5a (IC50 0.04 ± 0.01 μM), noncompetitively inhibited AChE with a higher potency than tacrine and gala

Synthesis, biological evaluation and molecular docking study of novel piperidine and piperazine derivatives as multi-targeted agents to treat Alzheimer's disease

Development of Multi-Target Directed Ligands (MTDLs) has emerged as a promising approach for targeting complex etiology of Alzheimer's disease (AD). Following this approach, a new series of N′-(4-benzylpiperidin-/piperazin-/benzhydrylpiperazin-1-yl)alkylamine derivatives were designed, synthesized and biologically evaluated as inhibitors of cholinesterases (ChEs), amyloid-beta (Aβ) self aggregation and also for their radical scavenging activity. The in vitro studies showed that the majority of synthesized derivatives strongly inhibited acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) with IC50 values in the low-nanomolar range, and were clearly more potent than the reference compound donepezil in this regard. Among them, inhibitors 5h and 5k, strongly inhibited AChE, with IC50 value of 6.83 nM and 2.13 nM, respectively, and particularly, compound 5k was found to be highly selective for AChE (～38-fold). Moreover, both kinetic analysis of AChE inhibition and the docking study suggested that 5k binds simultaneously to catalytic active site and peripheral anionic site of AChE. Besides, these compounds also exhibited greater ability to inhibit self-induced Aβ1-42 aggregation at 25 μM with percentage inhibition from ～54% to 89% and specially compound 5k provided highest inhibition (88.81%). Also, the derivatives containing methoxy and hydroxy groups showed potent oxygen radical absorbance capacity (ORAC) ranging from 2.2- to 4.4-fold of the Trolox value. Furthermore, results of ADMET studies suggested that all compounds exhibited appropriate drug like properties. Taken together, these results suggest that 5k might be a promising lead compound for further AD drug development.

RADIOLABELED COMPOUNDS AND METHODS THEREOF

The present invention relates to radiodiagnostic compounds, methods of making those compounds, and methods of use thereof as imaging agents for preferably a HA serotonin 5-HT1A receptor for use in PET or SPECT, preferably PET. Compositions comprising an imaging-effective amount of radiolabeled compounds are also disclosed. The present invention also relates to non-radiolabeled compounds, methods of making those compounds, and methods of use thereof to treat various neurological and/or psychiatric disorders.

Pyridine and pyridazine derivatives, processes for the production thereof and pharmaceutical agents containing these compounds

Compounds of Formula I STR1 in which the variables are defined herein, processes for the production thereof as well as pharmaceutical agents containing these compounds for the treatment of diseases which are the result of thromboembolytic events.

A structure-activity relationship study of novel phenylacetamides which are sodium channel blockers

A structure-activity relationship study of a series of novel Na+ channel blockers, structurally related to N-[3-(2,6-dimethyl-1-piperidinyl)propyl]- α-phenylbenzeneacetamide (1, PD85639) is described. The diphenylacetic acid portion of the molecule was left unchanged throughout the study, while structural features in the amine portion and the amide alkyl linkage of the molecule were modified. The compounds were tested for inhibition of veratridine-stimulated Na+ influx in CHO cells expressing type IIA Na+ channels. Several derivatives show a trend toward more potent Na+ channel blockade activity with increasing lipophilicity of the amine portion of the molecule. The presence of a phenyl ring near the amine increases inhibitory potency. A three-carbon spacer between the amide and amine is optimal, and a secondary amide linkage is preferred.